

FORTEO (teriparatide)

Effective Date: 1/28/14

Date Developed: 1/28/14 by Robert Sterling, MD

Last Approval Date: 1/26/16, 1/24/17

Unarchive: 1/22/19

(Archived: 1/1/18, 1/22/19)

Forteo is recombinant human parathyroid hormone (the primary regulator of calcium and phosphate metabolism in bone and kidney). Once-daily administration preferentially stimulates osteoblastic activity leading to new bone formation (as opposed to continuous excess produced in hyperparathyroidism, in which bone resorption predominates)

Pre-Authorization Criteria: postmenopausal women with osteoporosis at high risk for fracture, (history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy); glucocorticoid-Induced osteoporosis; men with primary or hypogonadal osteoporosis

Dosing: 20 mcg subcutaneously once a day

PRECAUTIONS: transient orthostatic hypotension (at the beginning of therapy); avoid in patients at increased risk of osteosarcoma (Paget's disease of bone; prior skeletal radiation therapy); monitor patients with known urolithiasis carefully; do not use for more than two years (no data beyond that point); ensure adequate calcium and vitamin D intake

DRUG INTERACTIONS: patients receiving digoxin should be monitored carefully for hypercalcemia (which predisposes to digitalis toxicity);

REFERENCES

Body JJ, Gaich GA, Scheele WH, et al, "A Randomized Double-blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1-34)] With Alendronate in Postmenopausal Women With Osteoporosis," *J Clin Endocrinol Metab*, 2002, 87(10):4528-35.

IOM (Institute of Medicine), *Dietary Reference Intakes for Calcium and Vitamin D*, Washington, DC: The National Academies Press, 2011.

National Osteoporosis Foundation (NOF), "Clinician's Guide to Prevention and Treatment of Osteoporosis," Washington, DC, 2013. Available at <http://www.nof.org/files/nof/public/content/resource/913/files/580.pdf>

Neer RM, Arnaud CD, Zanchetta JR, et al, "Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women With Osteoporosis," *N Engl J Med*, 2001, 344(19):1434-41.

Reeve, J, "Recombinant Human Parathyroid Hormone," *BMJ*, 2002, 324(7335):435-6.

Saag KG, Shane E, Boonen S, et al, "Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis," *N Engl J Med*, 2007, 357(20):2028-39.

REVISION HISTORY:

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD

Date Approved by P&T Committee: 1/27/15

Date Reviewed/Updated: 3/12/15 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/26/16

Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/24/17

Date Reviewed/Archived: 1/1/18 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/23/18

Date Reviewed/No Updates/Unarchived: 1/22/19 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/22/19

Date Reviewed/Archived: 1/22/19 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/22/19

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
---------------	--------------------------	--------------	-----------------------

1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/1/18	No	Catherine Sanders, MD; Robert Sterling, MD	Archived – excluded from Formulary effective 1/1/18
1/22/19	Yes	Catherine Sanders, MD; Robert Sterling, MD	Unarchived – Formulary Exclusion – For Exception Review Use Only Annual Review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Archived – check ESI